Alan A. Steigrod
Corporate Officer/Principal bij Newport Health Care Ventures
Profiel
Alan A.
Steigrod has been a Director of Sepracor, Inc. since 1995 and is a Member of the Audit Committee, the Nominating Committee and the Corporate Governance Committee.
He has been Managing Director of Newport HealthCare Ventures since January 1996.
Mr. Steigrod is a Director of NeoRx Corp.
and Lorus Therapeutics, Inc. Previously, he was President and Chief Executive Officer of Cortex Pharmaceuticals, Inc. from March 1993 to November 1995, President of Alan Steigrod Consulting from February 1991 to February 1993 and an Executive Vice President of Marketing and Sales for Glaxo, Inc. from March 1981 to February 1991.
Actieve functies van Alan A. Steigrod
| Bedrijven | Functie | Begin |
|---|---|---|
| Newport Health Care Ventures | Corporate Officer/Principal | 01-01-1996 |
Eerdere bekende functies van Alan A. Steigrod
| Bedrijven | Functie | Einde |
|---|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Directeur/Bestuurslid | 20-10-2009 |
Cellegy Pharmaceuticals, Inc.
 Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Directeur/Bestuurslid | 22-04-2009 |
| PONIARD PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 16-08-2006 |
| RESPIRERX PHARMACEUTICALS INC. | President | 01-11-1995 |
| Alan Steigrod Consulting | President | 01-02-1993 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| PONIARD PHARMACEUTICALS, INC. | Health Technology |
| RESPIRERX PHARMACEUTICALS INC. | Health Technology |
| APTOSE BIOSCIENCES INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Cellegy Pharmaceuticals, Inc.
Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Health Technology |
| Newport Health Care Ventures | |
| Glaxo, Inc. | |
| Alan Steigrod Consulting |
